CA
ELDN icon

Clearstead Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

Clearstead Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$363 Sell
92
-408
-82% -$1.48K ﹤0.01% 3028
2026
Q1 		$1.54K Hold
500
– – ﹤0.01% 1953
2025
Q4 		$755 Buy
+500
New +$1.19K ﹤0.01% 2262

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Clearstead Advisors's ELDN Position: Q2 2026 in Review

Clearstead Advisors reduced its Eledon Pharmaceuticals (ELDN) stake by 82% in Q2 2026, selling an estimated $1.48K and leaving 92 shares worth $363. The position accounts for ﹤0.01% of the portfolio, ranked #3028.

Clearstead Advisors first reported a position in ELDN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.54K in Q1 2026. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Clearstead Advisors held 92 shares of Eledon Pharmaceuticals worth $363 as of Q2 2026.
  • Clearstead Advisors sold 408 Eledon Pharmaceuticals shares in Q2 2026, an estimated $1.48K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3028 holding.
  • Clearstead Advisors first reported a position in Eledon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Clearstead Advisors's Eledon Pharmaceuticals position peaked at $1.54K in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.